BioSpace News Archive

Karuna Therapeutics, Inc. announced that data from the Phase 2 clinical trial evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia will be presented at the American Society of Clinical Psychopharmacology 2020 Annual Meeting, to be held virtually from May 29 to May 30, 2020.

Funding Will Support Delivery of Medically Tailored Meals to People Living with Kidney Failure and Those Struggling During COVID-19 Pandemic

Orphan drug designation granted for treatment (management) of pulmonary infections in patients with cystic fibrosis

DiamiR announced that it has received a notice of allowance from the United States Patent & Trademark Office for U.S. Patent Application No. 16/044,279 entitled “miRNA-based methods for detecting and monitoring aging.” The patent covers the use of methods developed by DiamiR based on targeted quantitative analysis of microRNAs enriched in the brain and detectable in blood plasma as biomarkers of brain aging.

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a company overview at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:30 PM ET. A

Automated “lateral flow” dispensing technology is vital step in rapid point-of-care antibody test production

Sensei Biotherapeutics , Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the acquisition of Alvaxa Biosciences, Inc., a camelid antibody therapeutics company with technology licensed from Fred Hutchinson Cance

Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present virtually at the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, at 12:40 p.m. Central Time. The link to the live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at https://investor.veracyte.com/events-

Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:00 p.m. Eastern Time. Jefferies Virtual Healthcare Conference Date: Wednesday, June 3 th , 2020 Time: 1:00 pm Eastern Time Webcast: Web

Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the underwriters of its previously announced underwritten public offering of its common stock have exercised in full their option to purchase 812,500 additional shares of common stock at the public offering price of $60.00 per share. The initial sale of 5,416,667 shares of commo